Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

First human trial: spinal fluid vaccine targets deadly breast cancer brain spread

NCT ID NCT05809752

Summary

This early-stage study is testing a personalized immune vaccine for breast cancer patients whose cancer has spread to the membranes surrounding the brain and spinal cord. Researchers will inject the vaccine directly into the spinal fluid to see if it's safe and to find the highest dose patients can tolerate. The goal is to see if this approach can help control this difficult-to-treat complication of breast cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    WITHDRAWN

    New York, New York, 10065, United States

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

  • Roswell Park Comprehensive Cancer Center

    WITHDRAWN

    Buffalo, New York, 14263, United States

Conditions

Explore the condition pages connected to this study.